Immunome Inc (NASDAQ: IMNM) open the trading on Thursday, with a bit cautious approach as it glided -2.47% to $9.86, before settling in for the price of $10.11 at the close. Taking a more long-term approach, IMNM posted a 52-week range of $8.97-$30.96.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 0.00% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -48.48%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 17.82%. This publicly-traded company’s shares outstanding now amounts to $60.42 million, simultaneously with a float of $51.30 million. The organization now has a market capitalization sitting at $615.43 million. At the time of writing, stock’s 50-day Moving Average stood at $11.64, while the 200-day Moving Average is $13.75.
Immunome Inc (IMNM) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Immunome Inc’s current insider ownership accounts for 17.80%, in contrast to 81.92% institutional ownership. According to the most recent insider trade that took place on Nov 21 ’24, this organization’s President and CEO bought 66,057 shares at the rate of 9.54, making the entire transaction reach 630,263 in total value, affecting insider ownership by 485,693. Preceding that transaction, on Nov 22 ’24, Company’s President and CEO bought 33,943 for 9.78, making the whole transaction’s value amount to 331,918. This particular insider is now the holder of 519,636 in total.
Immunome Inc (IMNM) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.69 per share during the current fiscal year.
Immunome Inc’s EPS increase for this current 12-month fiscal period is 17.82% and is forecasted to reach -3.11 in the upcoming year.
Immunome Inc (NASDAQ: IMNM) Trading Performance Indicators
Let’s observe the current performance indicators for Immunome Inc (IMNM). It’s Quick Ratio in the last reported quarter now stands at 6.17. The Stock has managed to achieve an average true range (ATR) of 0.82. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 60.75.
In the same vein, IMNM’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -8.12, a figure that is expected to reach -0.67 in the next quarter, and analysts are predicting that it will be -3.11 at the market close of one year from today.
Technical Analysis of Immunome Inc (IMNM)
[Immunome Inc, IMNM] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 23.02% While, its Average True Range was 0.83.
Raw Stochastic average of Immunome Inc (IMNM) in the period of the previous 100 days is set at 11.47%, which indicates a major fall in contrast to 26.27% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 65.25% that was lower than 71.88% volatility it exhibited in the past 100-days period.
